Market research
MACK Merrimack Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 224M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- Not available
- Beta
- 1.42
Community
Investor discussion
1 comment
Sign in to join the MACK discussion.
5 years, 4 months ago
Merrimack Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 2.4% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Merrimack Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 134.0% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 32.7% to $-2M since the same quarter in the previous year.
Based on the above factors, Merrimack Pharmaceuticals, Inc gets an overall score of 3/5.